Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price traded down 3.3% during mid-day trading on Wednesday . The company traded as low as $68.73 and last traded at $68.94. 336,743 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,066,961 shares. The stock had previously closed at $71.29.

Analysts Set New Price Targets

GPCR has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Morgan Stanley boosted their price objective on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.11.

Structure Therapeutics Price Performance

The stock’s 50-day moving average price is $40.36 and its 200-day moving average price is $27.92. The company has a market cap of $4.23 billion, a P/E ratio of -57.16 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Structure Therapeutics during the 3rd quarter valued at approximately $6,856,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Structure Therapeutics during the third quarter worth $10,440,000. Mariner LLC increased its holdings in shares of Structure Therapeutics by 11.7% during the third quarter. Mariner LLC now owns 44,136 shares of the company’s stock worth $1,236,000 after buying an additional 4,635 shares in the last quarter. National Bank of Canada FI lifted its stake in shares of Structure Therapeutics by 71,900.0% in the 3rd quarter. National Bank of Canada FI now owns 144,000 shares of the company’s stock valued at $4,032,000 after acquiring an additional 143,800 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Structure Therapeutics by 4.5% during the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.